TY  - JOUR
AU  - Saalfeld, Felix C
AU  - Wenzel, Carina
AU  - Christopoulos, Petros
AU  - Merkelbach-Bruse, Sabine
AU  - Reissig, Timm M
AU  - Laßmann, Silke
AU  - Thiel, Sebastian
AU  - Stratmann, Jan A
AU  - Marienfeld, Ralf
AU  - Berger, Johannes
AU  - Desuki, Alexander
AU  - Velthaus, Janna-Lisa
AU  - Kauffmann-Guerrero, Diego
AU  - Stenzinger, Albrecht
AU  - Michels, Sebastian
AU  - Herold, Thomas
AU  - Kramer, Michael
AU  - Herold, Sylvia
AU  - Tufman, Amanda
AU  - Loges, Sonja
AU  - Alt, Jürgen
AU  - Joosten, Maria
AU  - Schmidtke-Schrezenmeier, Gerlinde
AU  - Sebastian, Martin
AU  - Stephan-Falkenau, Susann
AU  - Waller, Cornelius F
AU  - Wiesweg, Marcel
AU  - Wolf, Jürgen
AU  - Thomas, Michael
AU  - Aust, Daniela E
AU  - Wermke, Martin
TI  - Brief Report: Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations.
JO  - Journal of thoracic oncology
VL  - 16
IS  - 11
SN  - 1556-0864
CY  - Amsterdam
PB  - Elsevier
M1  - DKFZ-2021-01557
SP  - 1952-1958
PY  - 2021
N1  - 2021 Nov;16(11):1952-1958
AB  - In contrast to other driver mutations, no targeted therapies have yet been approved in ERBB2 mutated non-small cell lung cancer (HER2mu NSCLC). However, several compounds have shown promising early efficacy data, which need to be evaluated in the context of current standard approaches. While data on the efficacy of immune checkpoint inhibitors (ICI) in second or later lines of treatment remain limited and conflicting, there are virtually no data on patient outcome under ICI / platinum doublet combinations in the first-line setting.We retrospectively assessed outcomes of HER2mu NSCLC patients treated with ICI alone or in combination with chemotherapy within the German nNGM consortium by means of overall response rate (ORR), progression-free, and overall survival (PFS and OS).ICI either in combination with chemotherapy or as monotherapy were applied as first-line treatment in 27 patients, whereas 34 received single agent ICI in second or later lines. Patient characteristics were in line with previously published data. In treatment-naïve patients receiving ICI in combination with chemotherapy the ORR, median PFS, and OS rate at 1 year were 52
KW  - HER2 (Other)
KW  - Immunotherapy (Other)
KW  - NSCLC (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:34245914
DO  - DOI:10.1016/j.jtho.2021.06.025
UR  - https://inrepo02.dkfz.de/record/169803
ER  -